What You Should Know:
- Cedars-Sinai Cancer and Tempus, a provider of artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients' DNA, RNA, protein and other information to help identify the most effective approach to each individual's disease.
- By creating these "molecular twins," scientists can genetically classify cancer genes and proteins of particular tumors
Read More
Tempus
CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform
What You Should Know:
- CancerIQ raises $5M in Series A funding led by HealthXVentures to accelerate the growth of its genetic cancer risk assessment platform to identify and manage patients at high risk of cancer.
- CancerIQ’s technology enables hospitals to use genomics
to personalize the prevention and early detection of cancer.
- Two new hires recently joined CancerIQ’s newly formed
Integrated Products team from Epic, with the goal of advancing CancerIQ’s
integration with leading
Read More
Philips Launches Pre-Hospital Wireless Monitoring Solution for Emergency Medical Response
What You Should Know:
- Philips receives 510(k) clearance from the FDA for its pre-hospital
wireless monitoring solution (Tempus LS- Manual), now offering its remote
monitor and defibrillator solution (Tempus ALS) to EMS customers in the U.S.
- Solution delivers real-time bidirectional data transfer
for remote patient monitoring, giving EMS responders a new approach to
pre-hospital care.
Philips, today announced the launch of its
remote monitoring and defibrillator solution
Read More
The Many Faces of AI in Clinical Trials
AI is being applied in several aspects for the clinical trial process today. From analyzing real-world data and scientific information to providing improved patient stratification and predictive outcomes, and assisting with different aspects of clinical trial operations. Here are some of the technologies using AI and machine learning in the clinical trial space today, outlining how they fit within the clinical trial ecosystem and discuss the impact on future clinical trial designs.
The
Read More
CVS Health Launches Transform Oncology Care Program, Partners with Tempus
- CVS Health launches Transform Oncology Care, which includes a comprehensive, first-of-its-kind precision medicine approach to oncology management for payors in collaboration with Tempus.- Transform Oncology Care includes an innovative precision medicine strategy that increases access to broad-panel gene sequencing tests for patients diagnosed with certain advanced-stage cancers. - The program also uses CVS’ local footprint and unique assets to improve patient outcomes and lower costs every
Read More
CB Insights Unveils ‘Digital Health 150’ List of Startups Transforming Healthcare
- CB Insights unveils first-ever annual ‘Digital Health 150’ list of digital health startups working to transform the healthcare industry.
- The Digital Health 150 companies span a wide spectrum of categories that involve all three key stakeholder groups for the healthcare industry — providers, payers, and patients.
- A total of 17 companies on the list are unicorns (private companies valued at $1B+). Of these, 12 companies are US-based, 3 are based in China, 1 is based in France, and 1
Read More
Tempus, Leidos Biomedical Research Inc. Launch Effort to Enhance The Cancer Genome Atlas
Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale announced today that it was selected by Leidos Biomedical Research Inc. (Leidos Biomed) to abstract and structure follow-up clinical data for The Cancer Genome Atlas (TCGA) Project for submission to the National Cancer Institute’s Genomic Data Commons (GDC).The Cancer Genome Atlas (TCGA) Project BackgroundThere are 230 distinct investigators that contributed
Read More
Data-Driven Precision Medicine Startup Tempus Lands $200M to Expand Into New Therapeutic Areas
Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an additional $200M financing at a value of $3.1 billion dollars. The investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth, and funds and accounts managed by T. Rowe Price. With this latest round, the company has raised $520 million since its founding in September 2015.Founded in 2015, Tempus has the largest
Read More
Tempus, Vanderbilt-Ingram Cancer Center Collaborate on Personalized Cancer Initiative
Tempus, a Chicago-based technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients. As part of the initial research project, Tempus will use its Tempus O platform to ingest and structure clinical data from the cancer center’s electronic health record. Tempus also will provide next generation
Read More
Tempus, Sanford Health Collaborate on Personalized Medicine Initiative to Identify Clinical Trials for Breast Cancer Patients
Tempus, a Chicago-based health IT technology company focused on collecting and integrating molecular and clinical data has announced a collaboration with Sanford Health to identify targeted therapies and clinical trials for breast cancer patients. Founded in 2015, Tempus continues to expand its network of partners and is currently working with leading academic medical centers, NCI designated cancer centers, hospital networks and community oncologists across the United States. As part of the
Read More
